YahooFinance

Moleculin Biotech Doubles In Pre-Market Trading On Potential Covid-19 Treatment

Moleculin Biotech (MBRX) today announced that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce the virus that causes COVID-19 by 100% in in vitro …

Tal Education Shares Plunge On Sales Fraud, Employee Wrongdoing

Shares in China’s after-school tutoring company Tal Education (TAL) have taken a battering after the company announced that an employee had ‘conspired with …

China’s Streaming Platform iQIYI Retaliates Against Short Seller Report

Chinese online entertainment service iQIYI Inc (IQ) has issued a statement denying allegations made in a short report by Wolfpack Research. In its …

SAGE Announces Massive Restructuring To Focus On Failed Depression Drug

Sage Therapeutics (SAGE) has announced a massive restructuring that appears to abandon the launch of post-partum depression drug Zulresso. “Zulresso is a hospital-based …

Pinterest Shares Climb 14% in After-Hours Trading On Positive Q1 Guidance

Photo-sharing site Pinterest (PINS) has released first quarter revenue guidance of $269- $272 million, bracketing the Street’s estimated $270 million, causing shares to …

Amazon Halts New Delivery Service To Focus On Demand Surge

E-commerce giant Amazon (AMZN) will suspend its delivery service for non-Amazon packages, according to people familiar with the matter, The Wall Street Journal reports. …

GenMark Sees 80% Q1 Revenue Boost on Covid-19 Tests

After the close on Tuesday, GenMark (GNMK) preannounced above-consensus 1Q20 revenue given tailwinds from COVID-19 testing. The molecular diagnostics company is now expecting …

Roku: Covid-19 to Impact Ad Revenue, Top Analyst Reduces Estimates

Bear markets are usually bad news for growth stocks. As sentiment in the market changes, these hotshots often tend to crash harder.

Is Apple Stock a Buy Right Now? This Is What You Need to Know

Is now the right time to unleash a new product? Whether it is or not, according to one analyst, Apple (AAPL) is readying …

Eli Lilly Lowers Insulin Cost in Response to Coronavirus Pandemic

Drugmaker Eli Lilly & Co (LLY) said on Tuesday it has reduced the out-of-pocket cost for insulin to $35 per month to help …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts